Browsing Tag
FDA Accelerated Approval
5 posts
Can Partner Therapeutics’ zenocutuzumab-zbco deliver a first-line breakthrough in NRG1+ lung cancer?
Zenocutuzumab-zbco by Partner Therapeutics shows durable first-line response in NRG1+ NSCLC. Find out what the new eNRGy trial data means for patients.
Sangamo Therapeutics shares surge 13% after FDA accepts rolling BLA for ST‑920 in Fabry disease
Sangamo Therapeutics shares surged 13% as the FDA accepted a rolling BLA for ST‑920 in Fabry disease. Learn what this milestone means and what’s next.
FDA grants accelerated approval for Bristol Myers Squibb’s Augtyro for NTRK-positive tumors
Bristol Myers Squibb (NYSE: BMY) has received accelerated FDA approval for Augtyro (repotrectinib), a treatment designed for patients…
Novartis reveals significant results for Fabhalta in IgAN study at World Congress of Nephrology
Novartis has achieved a major milestone in the treatment of IgA nephropathy (IgAN), reporting a 38.3% reduction in…
BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S.…